Cilgavimab and tixagevimab
Generic name: cilgavimab and tixagevimab
Brand name: Evusheld
Dosage form: intramuscular solution (150 mg/1.5 mL-150 mg/1.5 mL)
Drug class:Antiviral combinations
What is cilgavimab and tixagevimab?
Cilgavimab in combination with tixagevimab is an experimental medicine being studied for the prevention before exposure of COVID-19. It is not yet known if cilgavimab and tixagevimab is safe and effective.
The US Food and Drug Administration (FDA) has authorized emergency use of cilgavimab in combination with another medicine called tixagevimab for the prevention before exposure of COVID-19 in adults and people 12 years of age and older (weighing at least 40 kg or 88 lbs) who are not currently infected with COVID-19 and:
who have not had a known recent exposure to someone infected with COVID-19;
who are moderately to severely immunocompromised and may not get an adequate immune response to COVID-19 vaccination; or
for whom vaccination with any COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine.
Cilgavimab and tixagevimab is not authorized for use in people:
for treatment of COVID-19; or
for prevention after exposure of COVID-19 in people who have been exposed to someone infected with COVID-19.
Cilgavimab and tixagevimab is not a substitute for vaccination in people for whom COVID-19 vaccine is recommended. People who may benefit from COVID-19 vaccination should get vaccinated.
In people who have received a COVID-19 vaccine, cilgavimab and tixagevimab should be given at least 2 weeks after vaccination.
Cilgavimab and tixagevimab may also be used for purposes not listed in this medication guide.
Warnings
The US Food and Drug Administration (FDA) has authorized emergency use of cilgavimab in combination with another medicine called tixagevimab for the prevention before exposure of COVID-19 in adults and people 12 years of age and older (weighing at least 40 kg or 88 lbs).
Cilgavimab and tixagevimab have not been approved to treat coronavirus or COVID-19.
Before taking this medicine
You should not use cilgavimab and tixagevimab if you are allergic to it.
Tell your doctor if:
you had a COVID-19 vaccine;
you have heart problems;
you have a coagulation disorder or thrombocytopenia (low levels of platelets in the blood);
you are pregnant or breastfeeding; or
you have any serious or chronic disease.
COVID-19 is more likely to cause serious illness or death in a pregnant woman. Not all risks are known yet, but being treated with cilgavimab and tixagevimab is ...
